Dr. Darryl Steensma represents biotech, pharmaceutical, medical device, and diagnostics companies in a wide range of transactional matters.
Drawing on deep technical and subject matter experience as a biopharmaceutical scientist, Dr. Steensma advises clients developing life-saving innovations on their most critical partnerships and corporate transactions. He regularly counsels on matters regarding:
- Licensing and corporate partnering
- Co-promotion, co-marketing, and co-commercialization agreements
- University license agreements
- Research and collaboration agreements
- Asset purchases and mergers
- Manufacturing, distribution, and quality agreements
- Clinical trial collaboration and supply agreements
- Royalty stream purchases and sales
Dr. Steensma also represents investors and financial institutions in performing business, scientific, and intellectual property due diligence for private and public financings and mergers and acquisitions of life science companies.
Dr. Steensma is registered to practice before the US Patent and Trademark Office. His experience litigating on behalf of multinational and startup companies in pharmaceutical and life sciences litigation, including substantial representation in Hatch-Waxman litigation for both generic and branded pharmaceutical companies, informs his counsel on current and future patent portfolio strategies. He also advises clients on regulatory exclusivities and preparing citizen petitions to the FDA.
Prior to practicing law, Dr. Steensma held postdoctoral research positions at The Scripps Research Institute and at Georgetown University Medical Center. He is a named co-inventor on four US patents and is a co-author of over 10 peer-reviewed research publications.
Dr. Steensma is a member of the American Chemical Society, the AIPLA Biotechnology Committee, the BIOCOM Intellectual Property Committee, and the San Diego Intellectual Property Law Association.
Dr. Steensma’s recent representative transactions include:
- Amgen in its US$2.7 billion strategic collaboration with BeiGene to commercialize oncology drugs in China
- Allergan in its:
- Strategic research and development alliance with Editas Medicine
- Divestment of its global generic pharmaceuticals business and the rights to certain branded products to Teva for US$40.6 billion
- Ellipse Technologies in connection with its acquisition by NuVasive for US$380 million
- Fresenius Kabi in connection with its acquisition of the BD Rx pre-filled syringe business
- Ignyta in connection with its:
- Acquisition of four oncology R&D assets from Cephalon/Teva
- Acquisition of the Taladegib oncology program from Eli Lilly and Co.
- Ligand in connection with its acquisition of the genetic-engineering company OMT Inc. for US$178 million
- Numerous other clients in connection with strategic agreements and intellectual property transactions, including:
- Hale Biopharma Ventures
- Oncternal Therapeutics
- Shanghai Pharmaceuticals
- Swedish Orphan Biovitrum
- Telegraph Hill Partners
- Zentalis Pharmaceuticals